The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 102; no. 10; pp. e400 - e403
Main Authors Golay, Josée, Ubiali, Greta, Introna, Martino
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.10.2017
Subjects
Antibodies - drug effects
Antigens, CD20 - immunology
Benzamides - pharmacology
Benzamides - therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Online Only
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrazines - pharmacology
Pyrazines - therapeutic use
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2017.169334